Any current/future new fundraising through debt or equity?

Krsnaa Diagnostics aims to remain largely debt-free, relying primarily on internal accruals and vendor credit for funding. Debt may be considered if it proves to be a more efficient financing option for specific projects. Discussions are underway to adopt an asset-light pay-per-use model for equipment, reducing upfront capex needs. For upcoming capex, including potential Rajasthan tender-related investments, a combination of internal funds, vendor credit, and possible debt will be utilized. No explicit mention of raising funds through equity is noted in the provided transcript. The company emp

Any current/future capex/capital investment/strategic investment?

Planned capex for FY '25 (2024-25) is INR150-200 crores, excluding Rajasthan tender. Rajasthan tender capex, if won, is an additional INR200-250 crores, potentially raising total capex to INR450-500 crores over approximately one year. Capex mainly towards installing large, capex-heavy equipment such as analyzers and immunoassay machines. Exploring asset-light strategies including pay-per-use or lease models for equipment to reduce outright purchases. Capex funding through a mix of internal accruals, vendor financing, and possible debt if efficient, though company aims to remain largely debt-fr

Future growth expectations in sales/revenue/volumes?

Krsnaa Diagnostics expects a revenue growth CAGR of around 30% for FY '25, continuing the current growth trajectory. Expansion into more states and large projects such as Assam, Odisha, Rajasthan, and Maharashtra underpin this growth. New projects and tenders will add to gross block and incremental revenues as centers get implemented and mature. The company is becoming selective in tender participation, focusing on those aligned with financial metrics. B2C vertical is in early stages but expected to grow as brand acceptance and package sales increase. Rajasthan tender's revenue meaningful cont

Future growth expectations in earnings/operating earnings/profits/EPS?

Krsnaa Diagnostics anticipates sustained revenue growth at a CAGR of around 30% for FY '25, driven by ongoing and new project ramp-ups. EBITDA margins are expected to stabilize around 25%, given an increasing pathology mix which has slightly lower margins but offset by operational efficiencies. The company aims to maintain steady margins rather than pursuing aggressive improvement, adopting a conservative approach due to higher consumption costs in pathology. Asset maturity periods range from 9 months to 1.5 years, contributing to gradual improvement in returns on capital employed (ROCE), with

Current/ Expected Orderbook/ Pending Orders?

Krsnaa Diagnostics has won multiple PPP tenders from various states, including Assam, Odisha, Maharashtra, Rajasthan, and others. The Rajasthan pathology project is pending court approval with a judgment expected by end of February 2024; meaningful revenue expected only from H2 FY25. Maharashtra has completed installation of 9 out of 30 CT scan centers in phase 1, with full phase 1 expected within 2-3 quarters; additional new tender just signed. Assam and Odisha labs are being operationalized with all labs to be functional by Q4 FY24. New gross block additions of INR 150-200 crores expected ov

Krsnaa Diagnost.Q3 FY24Healthcare Services

Krsnaa Diagnost. Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹555P/E: 18.0Market Cap: ₹1.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Krsnaa Diagnostics expects a revenue growth CAGR of around 30% for FY '25, continuing the current growth trajectory.
Expansion into more states and large projects such as Assam, Odisha, Rajasthan, and Maharashtra underpin this growth.
New projects and tenders will add to gross block and incremental revenues as centers get implemented and mature.
The company is becoming selective in tender participation, focusing on those aligned with financial metrics.
B2C vertical is in early stages but expected to grow as brand acceptance and package sales increase.
Rajasthan tender's revenue meaningful contribution expected in the second half or Q4 of FY '25 after court decision and lab installations.
Increasing volume is a key growth driver, particularly given the PPP model which offers significant patient volumes.
The test mix is expected to remain around 60-65% radiology and 35-40% pathology, with a target to approach a 50-50 mix.

Margin guidance

Category 3

Krsnaa Diagnostics anticipates sustained revenue growth at a CAGR of around 30% for FY '25, driven by ongoing and new project ramp-ups.
EBITDA margins are expected to stabilize around 25%, given an increasing pathology mix which has slightly lower margins but offset by operational efficiencies.
The company aims to maintain steady margins rather than pursuing aggressive improvement, adopting a conservative approach due to higher consumption costs in pathology.
Asset maturity periods range from 9 months to 1.5 years, contributing to gradual improvement in returns on capital employed (ROCE), with mature assets delivering approximately 30% ROCE.
Net profits and EPS are expected to grow in line with revenue and margin stability, bolstered by a mix of internal accruals, vendor credit, and possible asset-light models reducing costs.
The Rajasthan tender, if cleared, will add significantly to top-line and asset base, with meaningful revenues projected from H2 FY '25 onward.

See what Krsnaa Diagnost. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Krsnaa Diagnostics aims to remain largely debt-free, relying primarily on internal accruals and vendor credit for funding.
Debt may be considered if it proves to be a more efficient financing option for specific projects.
Discussions are underway to adopt an asset-light pay-per-use model for equipment, reducing upfront capex needs.
For upcoming capex, including potential Rajasthan tender-related investments, a combination of internal funds, vendor credit, and possible debt will be utilized.
No explicit mention of raising funds through equity is noted in the provided transcript.
The company emphasizes minimizing debt and maintaining a strong balance sheet while pursuing growth opportunities.

Order book

Yes

Krsnaa Diagnostics has won multiple PPP tenders from various states, including Assam, Odisha, Maharashtra, Rajasthan, and others.
The Rajasthan pathology project is pending court approval with a judgment expected by end of February 2024; meaningful revenue expected only from H2 FY25.
Maharashtra has completed installation of 9 out of 30 CT scan centers in phase 1, with full phase 1 expected within 2-3 quarters; additional new tender just signed.
Assam and Odisha labs are being operationalized with all labs to be functional by Q4 FY24.
New gross block additions of INR 150-200 crores expected over next 1 to 1.5 years with upcoming projects.
Multiple states are exploring more PPP tenders due to positive reception of previous implementations, offering a growing pipeline.
Company is selective about tender participation ensuring alignment with financial metrics.

See what Krsnaa Diagnost. management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned capex for FY '25 (2024-25) is INR150-200 crores, excluding Rajasthan tender.
Rajasthan tender capex, if won, is an additional INR200-250 crores, potentially raising total capex to INR450-500 crores over approximately one year.
Capex mainly towards installing large, capex-heavy equipment such as analyzers and immunoassay machines.
Exploring asset-light strategies including pay-per-use or lease models for equipment to reduce outright purchases.
Capex funding through a mix of internal accruals, vendor financing, and possible debt if efficient, though company aims to remain largely debt-free.
New projects like Maharashtra MRI/CT and other state tenders will require incremental capex within the stated range.
Focus remains on selective tender participation aligned with financial metrics to optimize return on capital employed (ROCE).

Track Krsnaa Diagnost. — get its next earnings analysis in your feed

How does Krsnaa Diagnost. rank vs peers in Healthcare Services?

Pro feature

ThisKrsnaa Diagnost.

Rev 2Mar 3

See where Krsnaa Diagnost. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Krsnaa Diagnost. rank in Healthcare Services?

Compare Krsnaa Diagnost. against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Krsnaa Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →